Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Gynecologic Cancer
NCT06977594Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of Paclitaxel Micelles for Injection, carboplatin and dexamethasone in ovarian cancer, endometrial cancer (EC) and Cervical Cancer (CC) (6 arms), sponsored by Seoul National University Hospital. Primary endpoint: Incidence of hypersensitivity reactions. Started May 2025; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatindexamethasone
03
Conditions
ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06977594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977594.